Mind Medicine Inc. (MNMD), which recently successfully completed a phase IIb trial of its lead drug candidate, MM-120 ODT, in Generalized Anxiety Disorder, is on track to advance the compound into a late-stage trial this quarter.
MM-120 ODT is a pharmacologically optimized form of Lysergide D-tartrate (LSD) being developed for generalized anxiety disorder and other brain-based disorders. LSD was first synthesized in 1938, and its psychoactive properties were discovered in 1943.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com